8-K: TriSalus Exceeds 2025 Revenue Guidance, Projects Strong 2026

TriSalus Life Sciences announced preliminary Q4 and full-year 2025 revenues exceeding guidance, alongside robust 2026 revenue projections.

Summary

• Preliminary unaudited fourth quarter 2025 revenue reached approximately $13.2 million, marking a 60% year-over-year increase and 14% sequential quarterly growth.
• Preliminary unaudited full-year 2025 revenue totaled approximately $45.2 million, representing 53% year-over-year growth, which surpassed the company's 2025 guidance of 50%.
• Initial 2026 revenue guidance is set at approximately $60 million to $62 million.
• Cash and cash equivalents were estimated at approximately $20.4 million as of December 31, 2025.
• The company attributes its strong performance to the meaningful clinical adoption of its TriNav product suite and proprietary Pressure-Enabled Drug Delivery (PEDD) platform across various solid tumor indications.

Sentiment

Score: 8

Explanation: The company reported strong preliminary revenue growth for Q4 and full-year 2025, exceeding its own guidance, and provided robust 2026 revenue guidance. This indicates strong commercial execution and market adoption of its products. While there was a slight cash burn in Q4, the overall financial performance and strategic progress are highly positive, despite the preliminary nature of the results and inherent risks in clinical development.

Positives

• Fourth quarter 2025 revenue grew approximately 60% year-over-year to $13.2 million, demonstrating strong commercial momentum.
• Full-year 2025 revenue growth of approximately 53% to $45.2 million exceeded the company's 2025 guidance of 50%, highlighting effective execution.
• Strong commercial performance is driven by meaningful clinical adoption of the TriNav product suite and PEDD platform.
• Sustained progress on strategic initiatives includes the expansion of the TriNav platform across multiple indications beyond the liver and deepening engagement within the interventional radiology community.
• Positive initial 2026 revenue guidance of approximately $60 million to $62 million indicates an expectation of continued robust growth.

Negatives

• Cash and cash equivalents decreased by $2.3 million during the fourth quarter of 2025, from $22.7 million at the start of the quarter to $20.4 million at year-end.
• The financial results are preliminary and unaudited, subject to revisions based on year-end closing procedures and the completion of an external audit.
• The company may continue to raise capital through equity issuance to fund its operations, which could dilute existing shareholders.

Risks

• Actual financial results may differ materially from preliminary unaudited estimates due to year-end closing procedures, final adjustments, and audit completion.
• Uncertainty exists regarding the company's timeline to profitability, if it achieves profitability at all.
• Risks are associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including the possibility that future clinical results may not be consistent with current patient data.
• The cost and timing of all development activities and clinical trials are subject to variability.
• Unexpected safety and efficacy data may be observed during clinical studies.
• Risks are associated with the credit facility, including the company's ability to remain in compliance with all its obligations to avoid an event of default.
• There is a risk that the company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• Changes in expected or existing competition or market conditions could impact performance.
• Changes in the regulatory environment could affect product development and commercialization.
• Unexpected litigation or other disputes could arise.
• Unexpected expensed costs could impact financial results.

Future Outlook

The company anticipates full-year 2026 revenues to be in the range of approximately $60 million to $62 million. It also expects to complete data for several Phase 1 clinical trials for its investigational immunotherapeutic, nelitolimod, and subsequently begin exploring partnership opportunities for its development.

Management Comments

• "Continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications."
• "Pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community."
• "Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million."

Industry Context

This announcement highlights TriSalus Life Sciences' strong position and growth within the oncology medical technology sector. The company's focus on innovative drug delivery via its PEDD platform and TriNav system, coupled with the development of investigational immunotherapies like nelitolimod, places it at the forefront of addressing solid tumors. The reported revenue growth and strategic expansion across multiple indications and within the interventional radiology community suggest successful market penetration and adoption of its specialized technologies in a highly competitive and evolving healthcare landscape. The pursuit of a TLR9 agonist also aligns with broader industry trends in immuno-oncology, aiming to overcome tumor immunosuppression.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to directly assess the company's performance against global benchmarks.
• However, the reported 53% year-over-year revenue growth for 2025 and projected 2026 revenue guidance of $60-$62 million indicate a high growth trajectory, which is generally considered strong and favorable within the medical technology and oncology sectors, particularly for companies with proprietary and clinically adopted drug delivery platforms like PEDD.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong revenue growth, exceeding guidance, and positive future outlook, potentially leading to increased share value. However, the preliminary nature of results and potential future equity raises introduce some uncertainty.
• Employees: Continued growth and strategic progress may indicate job security and potential for expansion within the company.
• Customers (Healthcare Providers/Patients): Continued adoption and expansion of the TriNav and PEDD platform suggest positive clinical utility and potential for improved patient outcomes for solid tumors.
• Creditors: The company's ability to meet revenue requirements for credit facility access is a noted risk, but strong revenue growth generally improves creditworthiness and financial stability.

Next Steps

• Announce full-year 2025 financial results during an earnings conference call in March 2026.
• Complete data for a number of Phase 1 clinical trials for nelitolimod.
• Begin exploring partnership opportunities for nelitolimod development.

Key Dates

Recommendation

The company demonstrated exceptional preliminary revenue growth, exceeding its own guidance for 2025, and provided strong guidance for 2026, indicating robust market adoption of its innovative medical technology. The strategic progress in expanding its platform and advancing its immunotherapy candidate further strengthens its long-term potential. While the results are preliminary and a modest cash burn occurred in Q4, the overall trajectory and commercial execution are highly compelling for investors seeking growth in the oncology medical technology space.

Keywords

TriSalus Life Sciences, TLSI, oncology, medical technology, drug delivery, TriNav, PEDD platform, nelitolimod, immunotherapy, solid tumors, liver tumors, pancreatic tumors, financial results, revenue guidance, Q4 2025, full-year 2025, 2026 outlook